Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $34.90.
A number of research firms have recently weighed in on ALKS. Piper Sandler reiterated an “overweight” rating and set a $37.00 target price (down from $38.00) on shares of Alkermes in a report on Friday. HC Wainwright reiterated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research report on Friday. JPMorgan Chase & Co. decreased their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday. The Goldman Sachs Group dropped their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Finally, Robert W. Baird boosted their price objective on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th.
Get Our Latest Analysis on Alkermes
Hedge Funds Weigh In On Alkermes
Alkermes Trading Up 1.7 %
NASDAQ:ALKS opened at $26.53 on Tuesday. The firm has a market capitalization of $4.49 billion, a P/E ratio of 10.49, a P/E/G ratio of 0.56 and a beta of 0.46. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22. The company has a fifty day moving average of $27.80 and a 200 day moving average of $25.88. Alkermes has a 52 week low of $22.06 and a 52 week high of $32.88.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
- Five stocks we like better than Alkermes
- Investing in Commodities: What Are They? How to Invest in Them
- Inflation Risk Rising, Key Trades Investors Are Making Now
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Oil Stocks to Watch Before Earnings Come Out
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.